Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSCs for Liver Cirrhosis with Refractory Ascites
NCT01854125Phase 3Unknown
- Sponsor
- General Hospital of Eastern Military Command
- Start
- May 2013
- Primary completion
- Jan 2014
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of autologous bone-marrow mesenchymal stem cells in Liver cirrhosis (LC) (3 arms), sponsored by General Hospital of Eastern Military Command. Primary endpoints: change in immune function at 12 weeks, change in liver function in blood at 12 weeks and 1 more. Status: unknown.
02
Drugs
autologous bone-marrow mesenchymal stem cells
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT01854125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01854125.